Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Lenvatinib is an oral multikinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors 1 to 3 and other proangiogenic and oncogenic pathway-related receptor tyrosine kinases. To elucidate the origin of the potency of lenvatinib in VEGF receptor 2 (VEGFR2) inhibition, we conducted a kinetic interaction analysis of lenvatinib with VEGFR2 and X-ray analysis of the crystal structure of VEGFR2-lenvatinib complexes. Kinetic analysis revealed that lenvatinib had a rapid association rate constant and a relatively slow dissociation rate constant in complex with VEGFR2. Co-crystal structure analysis demonstrated that lenvatinib binds at its ATP mimetic quinoline moiety to the ATP binding site and to the neighboring region via a cyclopropane ring, adopting an Asp-Phe-Gly (DFG)-"in" conformation. These results suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several approved VEGFR2 kinase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lenvatinib is an oral TKI of VEGFRs, FGFRs, PDGFRα, KIT, and RET.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [20]
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, M. D., Gorbunova, V. A., Gore, M. E., Rusakov, I. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,840
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
CH/? hydrogen bonds in crystals
Nishio, M. (2004) · CrystEngComm · doi:10.1039/b313104a · Cited by 1,422
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Research works printed but not linked: 1
- Schlumberger M., 2014, ASCO Meet. Abstr., 32, LBA6008
Cited by
Items 201–300 of 306
Uchida‐Kobayashi, S., Kageyama, K., Takemura, S., Matsumoto, K., Odagiri, N., Jogo, A., Kotani, K., Kozuka, R., Motoyama, H., Kawamura, E., et al. (2022) · JGH Open · doi:10.1002/jgh3.12819 · Cited by 4
Vascular endothelial growth factor receptors (VEGFR/PDGFR) inhibitors
Elgawish, M. S., & Abdeldayem, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-96121-9.00017-6 · Cited by 5
Wang, M., Yao, X., Bo, Z., Zheng, J., Yu, H., Xie, X., Lin, Z., Wang, Y., Chen, G., & Wu, L. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s395474 · Cited by 4
“Lenvatinib is an oral multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR) 1–3, fibroblast growth factor receptors (FGFR) 1–3, RET, mast/stem cell growth factor receptor kit (SCFR), and oncogenic pathway-related receptor tyrosine kinases (RTKs).(10,11) Combining lenvatinib with other…”
BackgroundConversion therapy for massive hepatocellular carcinoma: A case report and literature review
Zhou, Z., Xu, X., Sun, M., Liu, Y., Liu, Q., Chen, C., & Yin, Y. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7533 · Cited by 4
Anticancer potential of quinazoline derivatives: Synthesis and molecular insights
Santoso, P., Danova, A., Aonbangkhen, C., Chatwichien, J., Natalia, D., Hermawati, E., Chavasiri, W., & Alni, A. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143593 · Cited by 3
Li, Y., Liu, S., Hu, S., Zhang, R., Wang, X., Xu, J., Yao, K., Lu, C., Li, G., Wu, Z., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01650 · Cited by 3
Damme, M. V., Elzo-Kraemer, X., Deman, A., Vulsteke, C., Dendooven, A., & Waele, L. D. (2026) · Acta Clinica Belgica · doi:10.1080/17843286.2026.2680287 · Cited by 3
“Although sorafenib also targets VEGFR1–3, its weaker VEGF-pathway potency at clinical doses [12] and lower reported proteinuria rates [5,10,11] suggest a comparatively lower nephrotoxic potential; however, this is inferred rather than conclusively demonstrated”
Xie, J., Zhang, X., Meng, D., Li, Y., & Deng, P. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2199082 · Cited by 3
“…et al., 2008; Hassan et al., 2022; Heyman et al., 2007; Kim et al., 2008; McTigue et al., 2012; Miyamoto et al., 2013; Modi & Kulkarni, 2019; Okamoto et al., 2014; Parikh & Ghate, 2018; Shi et al., 2018; Tripathy et al., 2007; Alanazi et al., 2021), and the decoy compounds were generated…”
BackgroundJin, X., Jiang, H., Guo, R., Zhao, H., Shen, L., Su, G., Li, S., Xu, J., & Guo, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108957 · Cited by 3
Inhibitors of Vascular Endothelial Growth Factor Receptor
Harris, P. A. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_28 · Cited by 3
The Efficacy and Safety of Lenvatinib in the Treatment of Solid Tumors: An Up-To-Date Meta-Analysis
Xie, W., Zhang, S., Su, L., Li, Y. H., Zhang, X., & Ran, Y. G. (2021) · Future Oncology · doi:10.2217/fon-2020-0327 · Cited by 3
Study on novel PtNP–sorafenib and its interaction with VEGFR2
Liu, R., Meng, Y., Zhu, M., Zhai, H. L., Lv, W., Wen, T., & Jin, N. (2021) · The Journal of Biochemistry · doi:10.1093/jb/mvab053 · Cited by 3
Alpinumisoflavone against cancer pro-angiogenic targets: In silico, In vitro, and In ovo evaluation
Alos, H. C., Billones, J. B., Castillo, A. L., & Vasquez, R. D. (2022) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-022-00445-9 · Cited by 3
“Particularly, the AIF showed the strongest binding affinity with MMP-9, VEGFR-2, and RET [17].”
BackgroundInfluentialCu(II), Ni(II) and Co(II) Complexes of Malonic Acid Dihydrazide with Bis-BrSalicylhydrazone
(2023) · Advances in Neurology and Neuroscience · doi:10.33140/an.06.02.05 · Cited by 3
Ansar, S., & Vetrivel, U. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13705 · Cited by 3
“…due to this mutation is not reported, hence was considered as wild type; Broecker-Preuss et al., 2015), BRAF V600E (Wan et al., 2004), KDR T940V (Okamoto et al., 2015), KIT mutant and KIT WT (Wilhelm et al., 2004) were also identified as top-ranking hits as per the maximal number of interaction…”
BackgroundWang, C., Feng, W. Q., Sun, X., Qiu, W., Yu, Y., Sun, D., Yao, Z., Li, J., Fan, Z., Lv, G., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1429919 · Cited by 3
Yalazan, H., Koç, D., Fandaklı, S., Tüzün, B., & Kantekın, H. (2024) · Eurasian Journal of Biological and Chemical Sciences · doi:10.46239/ejbcs.1517538 · Cited by 2
Cruz, F. S. D., Fox, E., DuBois, S. G., Friedman, G. K., Croop, J. M., Kim, A., Morgenstern, D. A., Balis, F. M., Macy, M. E., Pressey, J. G., et al. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31692 · Cited by 2
Sun, L. L., Xiao, Y., Li, Q., Wang, J., Zhu, X., Ji, W.-S., Xu, J., Li, X., Tang, Y., & Gao, F. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108799 · Cited by 2
Abdel-Hafez, G. A., Kłopotowska, D., Filip‐Psurska, B., Aboraia, A. S., Wietrzyk, J., Aboul‐Fadl, T., & Youssef, A. F. (2025) · RSC Advances · doi:10.1039/d5ra04997k · Cited by 2
Alminderej, F. M., & Aroua, L. M. (2026) · ChemistrySelect · doi:10.1002/slct.202504328 · Cited by 2
Cyclopropyl as a versatile tool in the development of kinase-targeted therapeutics
Liu, W., Huang, Y., Hao, W., Rong, Z., Liu, X., Zhou, Y., Song, S., & Pang, X. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118761 · Cited by 2
Yang, T., Wei, T., Sun, S., Xi, B., Wei, P., Jia, C., Qi, Z., Feng, F., Wei, M., Wang, Y., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03743 · Cited by 2
The role of long non-coding RNAs in therapy resistance of cervical cancer and therapeutic potential
He, Z., Hao, H., Li, X., Ji, Y., Zhao, K., Zhang, L., Jin, Y. C., & Wang, X. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1746979 · Cited by 2
Elgammal, W. E., Elkady, H., Mahdy, H. A., Taghour, M. S., Alsfouk, B. A. A., Eissa, I. H., Husein, D. Z., Amin, F. G., Elkaeed, E. B., & Metwaly, A. M. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146572 · Cited by 2
Endo, Y., Shimazu, M., Sakuragawa, T., Uchi, Y., Edanami, M., Sunamura, K., Ozawa, S., Chiba, N., & Kawachi, S. (2022) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v14.i3.260 · Cited by 2
Li, Y., Liu, X., Liu, J., Yang, L., Wei, S., Li, J.-J., Gan, H., Ma, T., & Yi, P. (2024) · Oncology Letters · doi:10.3892/ol.2024.14480 · Cited by 2
An update on the therapeutic options for metastatic thymomas and thymic carcinomas
Masui, Y., & Okuma, Y. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2519858 · Cited by 2
Development of Lenvatinib Mesylate, an Angiogenesis Inhibitor Targeting VEGF and FGF Receptors
Tsuruoka, A., Funahashi, Y., Matsui, J., & Matsushima, T. (2019) · Wiley eBooks · doi:10.1002/9783527814695.ch6 · Cited by 2
Self-citationChen, J.-N., Chen, C.-T., He, Y., Qin, T.-S., Cheng, L., Sun, Y., Yang, K.-J., Chen, Q., Yang, C., & Wei, Y. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00306b · Cited by 2
Kaur, M., Kaur, R., Saini, H., & Singh, P. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134819 · Cited by 2
Tsai, K.-L., Chang, S., & Yang, L. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.31.429052 · Cited by 4
Design, Synthesis and Biological Evaluation of Aryl Benzimidazole-Pyridones as Cytotoxic Agents
Sabita, G., Syed, T., Savitha, R., Divya, K., Nalla, S., & Bhaskar, K. (2023) · Synthetic Communications · doi:10.1080/00397911.2023.2292703 · Cited by 1
Uluçam, G. (2024) · Journal of the Mexican Chemical Society · doi:10.29356/jmcs.v68i3.1995 · Cited by 1
Three decades of kinase drug discovery: advances and challenges
Li, Z., Zhou, K., Wang, Z., & Ding, K. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0174 · Cited by 1
Takagawa, T., Takahashi, K., Orimoto, Y., Morisaki, Y., Suna, S., Daimon, T., Kijima, T., & Kuribayashi, K. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.12.010 · Cited by 1
Zi, Y., Chu, W., Ma, Y., Lan, J., Wang, W., Zhou, B., Shi, M., Wang, B., Chang, Q., & Li, W. (2026) · Biophysics Reports · doi:10.52601/bpr.2026.260002 · Cited by 1
Modh, D. H., Joshi, M., Patel, B. M., Deokar, H. S., Walhekar, V. S., & Kulkarni, V. M. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109992 · Cited by 1
Antitumor and resensitizing effects of wogonin in thyroid cancer via PDGFRB-dependent mechanisms
Ren, X., Yu, F., Chen, H. Z., Qin, X., Qiu, Z., & Luo, Q. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158328 · Cited by 1
Mansour, N. I., Ghaly, M. A., & El‐Gohary, N. S. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110187 · Cited by 1
A Structural Perspective on Non-covalent Targeting of Conserved Polar Residues in Protein Kinases
Nasief, N. N., Patel, K. B., Ogboo, B. C., & Heppner, D. E. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00330 · Cited by 1
Martins, B. B., Bresolin, L., de Farias, R. L., de Oliveira, A. B., & Gervini, V. C. (2017) · Acta Crystallographica Section E Crystallographic Communications · doi:10.1107/s2056989017008301 · Cited by 2
“The crystal structure of the vascular endothelial growth factor receptor-2 (VEGFR-2), PDB ID: 3WZD, was downloaded from Protein Data Bank (Okamoto et al., 2015).”
MethodInfluentialNawa, T., Katayama, K., Kiyota, R., Imai, T., Abe, Y., Hasegawa, N., Takada, R., Fukutake, N., Ikezawa, K., Sakakibara, M., et al. (2019) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-019-01021-6 · Cited by 1
Wu, W., Lai, J., Chen, J.-Y., & Liu, C. (2019) · Reports — Medical Cases Images and Videos · doi:10.3390/reports2030022 · Cited by 1
Yılmaz, A. Ş., & Kaçan, M. (2023) · ChemistrySelect · doi:10.1002/slct.202300150 · Cited by 1
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00001-9 · Cited by 1
Kawano, S., Fukushima, S., Nishibata, K., Gejima, R., & Miyano, S. W. (2025) · Cancers · doi:10.3390/cancers17071084 · Cited by 1
“Tasurgratinib, formerly known as E7090, is an orally available FGFR1–3 selective inhibitor that belongs to a unique class of tyrosine kinase inhibitors, type V, with high affinity for target proteins and selectivity for a small number of receptor tyrosine kinases [16–18].”
Othman, E. M., Othman, D. I. A., Bayoumi, W. A., Habib, E. E., & El‐Messery, S. M. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143282 · Cited by 1
Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR
Lima, L. M., Barbosa, M. L. D. C., do Amaral, D. N., & Barreiro, E. J. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_95 · Cited by 2
Place du lenvatinib dans les cancers thyroïdiens réfractaires à l’iode
de la Fouchardière, C. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.10.002
Structural study of the therapeutic potential of protein-ligand interactions
Martínez-Jiménez, F. (2016) · Repositori digital de la UPF (Universitat Pompeu Fabra)
11C-Sorafenib and 15O-H2O PET for Early Evaluation of Sorafenib Therapy
Mammatas, L. H., Yaqub, M. M., Hendrikse, N. H., Hoekstra, O. S., Honeywell, R. J., Schuit, R. C., Meijerink, M. R., Schwarte, L. A., Peters, G. J., Verheul, H. M. W., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.251611
“Previously, the target binding kinetics have been shown to be slower for sorafenib than for sunitinib and lenvatinib, for example, and therefore the 1-h scanning time may have been too short to reflect drug–target occupation after 14 d of continuous sorafenib treatment (32,33).”
BackgroundUS FDA‐Approved Small‐Molecule Kinase Inhibitors for Cancer Therapy
Yu, M., Tadesse, S., & Wang, S. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc214.pub2
PhD, E. V. (2018) · Wiley eBooks · doi:10.1002/9781119126843.ch4
Saudale, F. Z. (2020) · ALKIMIA Jurnal Ilmu Kimia dan Terapan · doi:10.19109/alkimia.v4i1.5148 · Cited by 2
Tavares, M. T. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2019.tde-14102022-153532
Corey, E. J., & Wu, Y. (2023) · Wiley eBooks · doi:10.1002/9781394207145.ch5
Shinkar, S. S., Bhairi, S. R., Khedkar, P. M., Dhande, S. R., & Jagdale, D. M. (2023) · INDIAN DRUGS · doi:10.53879/id.60.09.13805
[Chinese expert guidance on overall application of lenvatinib in hepatocellular carcinoma].
Yang, X., Sun, H., Xie, Q., Zhang, W. G., Jia, W., Zhao, M. D., Zhao, H. T., Liu, X. F., Zhou, L., Yan, S., et al. (2023) · PubMed Central · doi:10.3760/cma.j.cn115610-20230201-00035-1 · Cited by 2
Yen‐Pon, E. (2016) · theses.fr (ABES) · doi:10.70675/ded8ef98zd2bez46b7za8dcz50207dbd3d66 · Cited by 1
Atropisomerism in Drug Discovery and Development
Darwish, K. M., Yassen, A. S. A., Husseiny, E. M., Hamed, M. I. A., & Helal, M. A. (2024) · Wiley eBooks · doi:10.1002/9783527844258.ch11
SYNTHESIS OF NEW COUMARIN DERIVATIVES AND EVALUATION OF THEIR ANTI-CANCER ACTIVITY
Le, T. T. (2024) · Tạp chí Khoa học · doi:10.54607/hcmue.js.21.9.4241(2024
An Overview of Protein Kinase Inhibitors
De, S. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-75682-5_1
Keerthan, K. B., Srivatsan, S., Maithra, N., Chethan, B. S., Pruthviraj, K., Niranajna, S. V., Chen, C., Sunil, K., & Lokanath, N. K. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.141552
Xiao, Y., Sun, L., Ji, W.-S., Xu, J., Li, X., Tang, Y., & Gao, F. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5165720
Novel Strategy against AML by Rescuing Loss of Phase Separation of Pathogenic NPM1cPreprint
Zhu, Y., Xu, W., Wang, R., Hu, L., Huang, X., Zhu, H.-H., & Li, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.08.646961
Xiao, Y., Sun, L., Li, Q., Wang, J., Zhu, X.-X., Ji, W.-S., Xu, J., Li, X., Tang, Y., & Gao, F. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5249884
Patel, R. P., & Varghese, J. F. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_9
2-Chloro-4-hydroxyanilinium chloride
Bai, S. V., Mensah, P. F., Li, G., Fronczek, F. R., & Uppu, R. M. (2025) · IUCrData · doi:10.1107/s2414314625008934
Fouad, M. A., Osman, A. A., Abdelhamid, N. M., Rashad, M. W., Nabawy, A. Y., & Kerdawy, A. M. E. (2024) · Figshare · doi:10.6084/m9.figshare.25210675
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Figshare · doi:10.6084/m9.figshare.21301428
Abdel‐Mohsen, H. T., Ibrahim, M. A., Nageeb, A. M., & Kerdawy, A. M. E. (2024) · Figshare · doi:10.6084/m9.figshare.26684973
Cardiovascular safety liabilities of VEGFR-2 inhibitors
Pannucci, P. (2024)
Mancini, A. (2020) · Electronic Theses and Dissertations Repository (University of Pisa)
Hepishy, I. M., Sakr, H. M., Khedr, F., El‐Adl, K., & Salem, M. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.145575
Pharmacophore-driven kinase profiling applied to the PKIS2 chemogenomic dataset
Bureau, R., Lamotte, J., Cuissart, B., & Lepailleur, A. (2026) · Scientific Reports · doi:10.1038/s41598-026-42945-7
Braka, A. (2018) · theses.fr (ABES) · doi:10.70675/1e0f3ce5zad11z451bz82f0zaf383a726ad1 · Cited by 1
Fukushima, M., Nakao, Y., Sasaki, R., Haraguchi, M., Miuma, S., & Miyaaki, H. (2026) · World Journal of Clinical Cases · doi:10.12998/wjcc.v14.i15.119781
肝細胞癌に対するレンバチニブ療法の臨床効果に及ぼすNOS3遺伝子多型の影響
Azuma, S. (2021) · Institutional Repositories DataBase (IRDB)
Tan, E., Modi, N. D., Hassankhani, R., Martin, H., van Dyk, M., Spencer, S. M., Sallustio, B. C., & Kichenadasse, G. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552261459659
Meziani, O., Ferkous, F., Kaki, S. A., Kraim, K., Saihi, Y., Mohammed, M. M. D., & Osman, A. M. A. (2026) · Chemical Papers · doi:10.1007/s11696-026-05026-7
“Notwithstanding, the area of the center structural fold that includes the active site residues (i.e., Leu840, Gly841, Ala866, Glu917, Cys919, Cys1045, etc.) of the protein, represents RMSF values below 2.0 Å.”
InfluentialKong, Z., Xie, F., Xu, Z., Zhao, Y., Yu, S., Zhang, J., Ma, R., 唐龙骞, Wu, J., Ma, C., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119071
Osanai, H., Kozaka, K., Matsubara, T., Yoneda, N., Ogi, T., Okumura, K., Takamatsu, A., Kitao, A., Yagi, S., Yamashita, T., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70228
Ding, X., Wei, H., Ye, M., Huang, Y., Su, A., Ding, X., Chen, W., Tang, Z., & Ma, J. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11628-w
Elwan, A., Alshabani, L. A., Mabrouk, R. R., Zaki, A. B., Abbas, M., Celik, I., Turky, A., El‐Shershaby, M. H., Alswah, M., & Abdallah, A. E. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.147239
Şahın, Ç., Arabaci, U., Aydın, G., Yerlikaya, P. O., & Kılınçarslan, R. (2026) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2026.113428
Minh, V. L., Hung, N., Anh, P. T., Pham, A. T., & Thông, P. M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176839
“Lenvatinib inhibits VEGF receptors 1–3, FGF receptors 1–4, RET, KIT, and platelet-derived growth factor receptor alpha, providing a biologically plausible complement to TACE [9].”
Nicotinonitriles-based therapeutics as versatile pharmacophores in rational anticancer drug design
Nafie, M. S., Zeidan, M. A., Fahmy, S. A., Diab, M. K., Darwish, K. M., & Yassen, A. S. A. (2026) · RSC Advances · doi:10.1039/d6ra05778k
Efficacy and Safety of Lucitanib in Advanced Thymic Carcinoma: A Randomized Phase II Trial
Fang, W., Zhou, C., Wang, C., Wu, K., Fu, J., 林晓燕, Zhang, H., Jianhua, C., Zhang, P., Zhang, Y., et al. (2026) · MedComm · doi:10.1002/mco2.71105
“In this context, prior studies have shown that lenvatinib exhibits rapid binding and slow dissociation from VEGFR2 [ 12 ], while sunitinib and sorafenib can directly induce keratinocyte apoptosis or intracellular drug accumulation, thereby exacerbating epithelial toxicity [ 13, 14 ].”
BindingDB (2026) · UC San Diego · doi:10.7270/q2q81jzf
BindingDB Entry 50015529: Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
BindingDB (2023) · UC San Diego · doi:10.7270/q2xs6097
BindingDB (2018) · UC San Diego · doi:10.7270/q2j10591
BindingDB Entry 50003228: Recent developments in small molecule therapies for renal cell carcinoma.
BindingDB (2020) · UC San Diego · doi:10.7270/q2ws8wzz
Metadata
- Authors
- Okamoto, K., Ikemori-Kawada, M., Jestel, A., von König, K., Funahashi, Y., Matsushima, T., Tsuruoka, A., Inoue, A., & Matsui, J.
- Affiliations
- Eisai (Japan) (JP)
- Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan
- Proteros Biostructures GmbH, Planegg-Martinsried, Germany
- Eisai (United States) (US)
- Corresponding author
- Matsui, Junji
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-11-20
- Volume
- 6
- Issue
- 1
- Pages
- 89-94
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC4291723
- OpenAlex
- W1976262446
- Cited by
- 285
- References
- 28
- Citations by year
- 2026: 32 · 2025: 29 · 2024: 31 · 2023: 27 · 2022: 30 · 2021: 40 · 2020: 24 · 2019: 23 · 2018: 19 · 2017: 12 · 2016: 11 · 2015: 7
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- lenvatinib, VEGFR2, multikinase inhibitor, ATP binding site, binding kinetics, crystal structure, receptor tyrosine kinase inhibition, VEGF receptor inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.